A detailed history of Cubist Systematic Strategies, LLC transactions in Uni Qure N.V. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 226,057 shares of QURE stock, worth $3.92 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
226,057
Previous 25,494 786.71%
Holding current value
$3.92 Million
Previous $114,000 877.19%
% of portfolio
0.01%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.78 - $10.12 $758,128 - $2.03 Million
200,563 Added 786.71%
226,057 $1.11 Million
Q2 2024

Aug 14, 2024

BUY
$4.39 - $5.43 $63,453 - $78,485
14,454 Added 130.92%
25,494 $114,000
Q1 2024

May 15, 2024

SELL
$4.82 - $6.93 $1.27 Million - $1.83 Million
-263,408 Reduced 95.98%
11,040 $57,000
Q4 2023

Feb 14, 2024

BUY
$5.63 - $8.27 $435,120 - $639,155
77,286 Added 39.2%
274,448 $1.86 Million
Q3 2023

Nov 14, 2023

BUY
$6.71 - $11.83 $1.32 Million - $2.33 Million
197,162 New
197,162 $1.32 Million
Q4 2022

Feb 14, 2023

BUY
$18.12 - $27.32 $1.3 Million - $1.95 Million
71,524 Added 6461.07%
72,631 $1.65 Million
Q1 2022

May 16, 2022

SELL
$14.54 - $21.5 $17,215 - $25,456
-1,184 Reduced 51.68%
1,107 $20,000
Q4 2021

Feb 14, 2022

SELL
$20.24 - $36.01 $232,962 - $414,475
-11,510 Reduced 83.4%
2,291 $48,000
Q3 2021

Nov 15, 2021

SELL
$26.01 - $38.22 $348,325 - $511,842
-13,392 Reduced 49.25%
13,801 $442,000
Q2 2021

Aug 16, 2021

BUY
$29.97 - $37.17 $410,379 - $508,968
13,693 Added 101.43%
27,193 $838,000
Q1 2021

May 17, 2021

SELL
$29.24 - $42.03 $52,982 - $76,158
-1,812 Reduced 11.83%
13,500 $455,000
Q4 2020

Feb 16, 2021

BUY
$35.35 - $50.67 $237,269 - $340,097
6,712 Added 78.05%
15,312 $553,000
Q3 2020

Nov 16, 2020

SELL
$35.98 - $47.66 $60,806 - $80,545
-1,690 Reduced 16.42%
8,600 $317,000
Q2 2020

Aug 14, 2020

BUY
$45.06 - $67.74 $463,667 - $697,044
10,290 New
10,290 $464,000
Q1 2020

May 15, 2020

SELL
$40.01 - $73.97 $175,563 - $324,580
-4,388 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$37.13 - $74.62 $24,208 - $48,652
-652 Reduced 12.94%
4,388 $314,000
Q3 2019

Nov 14, 2019

SELL
$39.36 - $76.8 $108,200 - $211,123
-2,749 Reduced 35.29%
5,040 $198,000
Q2 2019

Aug 14, 2019

BUY
$52.76 - $82.19 $410,947 - $640,177
7,789 New
7,789 $609,000
Q4 2018

Feb 14, 2019

SELL
$22.8 - $33.93 $143,320 - $213,283
-6,286 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$29.75 - $43.08 $550,285 - $796,850
-18,497 Reduced 74.64%
6,286 $229,000
Q2 2018

Aug 14, 2018

BUY
$21.96 - $39.94 $544,234 - $989,833
24,783 New
24,783 $937,000
Q1 2018

May 15, 2018

SELL
$17.1 - $26.61 $9,148 - $14,236
-535 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$9.47 - $19.59 $5,066 - $10,480
535
535 $10,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $811M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.